Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
America's sunscreen aisle is about to get a major upgrade. The FDA has officially permitted bemotrizinol (PARSOL Shield) in U.S. sunscreen formulations — the first new active sunscreen ingredient since 1999. It offers broad-spectrum UVA and UVB protection, doesn't absorb into the bloodstream, leaves no white cast, and is safe for babies as young as 6 months. Expect to see it on store shelves as early as this fall.
America's sunscreen aisle is about to get a serious upgrade. The FDA has officially added bemotrizinol — marketed as PARSOL Shield by dsm-firmenich — to its over-the-counter sunscreen monograph, making it the first new active sunscreen ingredient permitted in the U.S. since 1999. The FDA effective date hit on Aug. 9, 2026, and major brands like Neutrogena, CeraVe, and La Roche-Posay have already announced plans to launch products containing the ingredient, with some expected on shelves as early as September or October 2026.
So what makes bemotrizinol stand out? Unlike most U.S. sunscreens that rely on a combination of filters to cover both UVA and UVB rays, bemotrizinol delivers broad-spectrum protection on its own. It's also highly photostable — meaning it doesn't break down quickly in sunlight — sits on top of the skin rather than absorbing into the bloodstream, and won't leave a white cast, a common complaint with mineral sunscreens. It's the first chemical sunscreen filter to earn the FDA's "generally recognized as safe and effective" (GRASE) designation.
Key Takeaways:
Why it matters: The U.S. has long lagged behind Europe and Asia in sunscreen innovation — many other countries have nearly twice as many approved UV filters. Bemotrizinol's approval signals a new era for American photoprotection, potentially paving the way for additional advanced filters and better skin cancer prevention tools for a broader range of consumers.
